The results showed that ALKBH5 mRNA expression levels significantly correlated with the prognosis of glioma patients with different IDH mutations, 1p/19q codeletion, and MGMT promoter status; the high mRNA expression of ALKBH5 negatively correlated with the prognosis of glioma patients in the CGGA_325 and CGGA_693 datasets (Supplementary Figures 7A–C). Here, MGMT is linked to central nervous system cancer.